Emerging Drugs and Targets for Alzheimer's Disease: Volume 2: Neuronal Plasticity, Neuronal Protection and Other Miscellaneous Strategies
Alzheimer's disease is the most prevalent neurodegenerative disorder in the elderly. A recent study from the Bloomberg School of Public Health recently estimated that over 26 million people were living with the disease in 2006 and that the global prevalence of the disease will grow to 106 million by 2050. By that time, 43 per cent of those living with the disease will need high-level care, equivalent to that of a nursing home. However, even if modest advances in preventing or delaying the disease's progression were made, it could have a huge impact on global public health. According to this study, interventions that could delay the onset of the disease by as little as one year would reduce the prevalence of the disease by 12 million fewer cases in 2050. These figures reinforce how important it is to find an effective intervention for Alzheimer's disease.
Emerging Drugs and Targets for Alzheimer's Disease collects some of the most outstanding examples of new drugs currently under pharmaceutical development or new targets in the validation process that will reach the Alzheimer's drug market over the next few years as disease modifying drugs. Written by a team of distinguished experts, these volumes are an essential resource for scientists in the pharmaceutical and biotechnology industries and academics working in the neurosciences field.
Emerging Drugs and Targets for Alzheimer's Disease: Volume 2: Neuronal Plasticity, Neuronal Protection and Other Miscellaneous Strategies, The Royal Society of Chemistry, 2010.
Download citation file:
Digital access
Print format
Table of contents
-
Regeneration of Degenerated Brain: A Promising Therapeutic Targetp3-20ByInge Grundke-Iqbal;Inge Grundke-IqbalDepartment of Neurochemistry, New York State Institute for Basic Research in Developmental Disabilities1050 Forest Hill RoadStaten IslandNY 10314-6399USASearch for other works by this author on:Khalid IqbalKhalid IqbalDepartment of Neurochemistry, New York State Institute for Basic Research in Developmental Disabilities1050 Forest Hill RoadStaten IslandNY 10314-6399USASearch for other works by this author on:
-
Chapter 16: Promoting Synaptic Resilience in Alzheimer's Disease Patients Through Phosphodiesterases Inhibitionp21-42ByKelly R. Bales;Kelly R. BalesNeuroscience BiologyPfizer Global Research & DevelopmentGrotonCT 06355USASearch for other works by this author on:Frank S. MennitiFrank S. MennitiNeuroscience BiologyPfizer Global Research & DevelopmentGrotonCT 06355USASearch for other works by this author on:
-
Chapter 17: A New Generation of Noninvasive NGF-Based Therapies for Alzheimer's Diseasep43-77ByAntonino Cattaneo;Antonino CattaneoEuropean Brain Research Institute (EBRI) – Rita Levi Montalcini FoundationVia del Fosso di Fiorano 6400143RomeItalyScuola Normale SuperiorePiazza dei Cavalieri 756126PisaItalySearch for other works by this author on:Simona Capsoni;Simona CapsoniEuropean Brain Research Institute (EBRI) – Rita Levi Montalcini FoundationVia del Fosso di Fiorano 6400143RomeItalySearch for other works by this author on:Francesca PaolettiFrancesca PaolettiEuropean Brain Research Institute (EBRI) – Rita Levi Montalcini FoundationVia del Fosso di Fiorano 6400143RomeItalySearch for other works by this author on:
-
Chapter 18: Possible Clinical Applications of Stem-Cell Strategies in AD Therapiesp78-94ByKiminobu SugayaKiminobu SugayaBurnet School of Biomedical Science, College of Medicine, University of Central FloridaOrlandoFloridaUSASearch for other works by this author on:
-
Chapter 19: Targeting Oxidative Mechanisms in Alzheimer Diseasep97-107ByHyun P. Lee;Hyun P. LeeDepartment of Pathology, Case Western Reserve UniversityClevelandOhioUSASearch for other works by this author on:Raj K. Rolston;Raj K. RolstonGeisinger Medical CenterDanvillePennsylvaniaUSASearch for other works by this author on:Xiongwei Zhu;Xiongwei ZhuDepartment of Pathology, Case Western Reserve UniversityClevelandOhioUSASearch for other works by this author on:Michael W. Marlatt;Michael W. MarlattSwammerdam Institute for Life Sciences – Center for Neuroscience, University of AmsterdamAmsterdamThe Netherlands and Marie Curie Early Stage Training Program – NEURAD Graduate SchoolGöttingenGermanySearch for other works by this author on:Rudy J. Castellani;Rudy J. CastellaniDepartment of Pathology, University of MarylandBaltimoreMarylandUSASearch for other works by this author on:Akihiko Nunomura;Akihiko NunomuraDepartment of Neuropsychiatry, Interdisciplinary Graduate School of Medicine and Engineering, University of YamanashiChuoYamanashiJapanSearch for other works by this author on:Hyoung-gon Lee;Hyoung-gon LeeDepartment of Pathology, Case Western Reserve UniversityClevelandOhioUSASearch for other works by this author on:Gemma Casadesus;Gemma CasadesusDepartment of Neurosciences, Case Western Reserve UniversityClevelandOhioUSASearch for other works by this author on:George Perry;George PerryDepartment of Pathology, Case Western Reserve UniversityClevelandOhioUSACollege of Sciences, University of Texas at San AntonioSan AntonioTexasUSASearch for other works by this author on:Mark A. SmithMark A. SmithDepartment of Pathology, Case Western Reserve UniversityClevelandOhioUSASearch for other works by this author on:
-
Chapter 20: Davunetide (NAP) Pharmacology: Neuroprotection and Taup108-128ByIllana GozesIllana GozesThe Adams Super Center for Brain Studies, The Lily and Avraham Gildor Chair for the Investigation of Growth Factors, The Elton Laboratory for Neuroendocrinology, Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv UniversityTel Aviv69978IsraelSearch for other works by this author on:
-
Chapter 21: Targeting NF-κB Inflammatory and Prosurvival Signalling in Alzheimer's Diseasep129-152ByStefan Keslacy;Stefan KeslacyDepartment of Exercise Science @ Syracuse UniversitySyracuseNew York13210USASearch for other works by this author on:Mary Lou VallanoMary Lou VallanoDepartment of Neuroscience & Physiology @ Upstate Medical UniversitySyracuseNew York13210USASearch for other works by this author on:
-
Chapter 22: PPARγ in Alzheimer's Diseasep153-165ByMichael T. Heneka;Michael T. HenekaUniversity Hospital Bonn, Department of Neurology, Clinical NeuroscienceSigmund-Freud-Straße 2553127 BonnGermanySearch for other works by this author on:Markus P. KummerMarkus P. KummerUniversity Hospital Bonn, Department of Neurology, Clinical NeuroscienceSigmund-Freud-Straße 2553127 BonnGermanySearch for other works by this author on:
-
Chapter 23: Serotonin 5-HT4 Receptors as Pharmacological Targets for the Treatment of Alzheimer's Diseasep169-190ByIsabelle Berque-Bestel;Isabelle Berque-BestelINSERM U869F-33076BordeauxFranceARNA; Université Victor SegalenF-33076BordeauxFranceSearch for other works by this author on:Frank Lezoualc'hFrank Lezoualc'hINSERM UMR-S 769F-92296Châtenay-MalabryFranceIFR-141, Faculté de Pharmacie, Université Paris-SudF-92296Châtenay-MalabryFranceSearch for other works by this author on:
-
Chapter 24: Targeting ApoE in Alzheimer's Disease: Liver X Receptor Agonists as Potential Therapeuticsp191-212ByDavid R. Riddell;David R. RiddellNeuroscience Research Unit, Pfizer Global Research and DevelopmentCN8000PrincetonNJ 08543USASearch for other works by this author on:David J. O'NeillDavid J. O'NeillChemical and Screening SciencePfizer Global Research and Development500 Arcola RoadCollegevillePA 19426USASearch for other works by this author on:
-
Chapter 25: Discovery of Memoquin, a Multitarget-Directed Ligand (MTDL) for the Treatment of Alzheimer's Diseasep213-227ByM. Laura Bolognesi;M. Laura BolognesiDepartment of Pharmaceutical Sciences, Alma Mater Studiorum, University of BolognaVia Belmeloro 640126 BolognaItalySearch for other works by this author on:Anna Minarini;Anna MinariniDepartment of Pharmaceutical Sciences, Alma Mater Studiorum, University of BolognaVia Belmeloro 640126 BolognaItalySearch for other works by this author on:Carlo MelchiorreCarlo MelchiorreDepartment of Pharmaceutical Sciences, Alma Mater Studiorum, University of BolognaVia Belmeloro 640126 BolognaItalySearch for other works by this author on:
-
Chapter 26: RNA Interference of Genes Related to Alzheimer's Diseasep228-268ByBarbara Nawrot;Barbara NawrotCentre of Molecular and Macromolecular StudiesPolish Academy of SciencesSienkiewicza 112Lodz 90-363PolandSearch for other works by this author on:Malgorzata Sierant;Malgorzata SierantCentre of Molecular and Macromolecular StudiesPolish Academy of SciencesSienkiewicza 112Lodz 90-363PolandSearch for other works by this author on:Alina PaduszynskaAlina PaduszynskaCentre of Molecular and Macromolecular StudiesPolish Academy of SciencesSienkiewicza 112Lodz 90-363PolandSearch for other works by this author on:
-
Chapter 27: Medicinal Plants, Phytochemicals and Alzheimer's Diseasep269-290ByDavid O. Kennedy;David O. KennedyBrain, Performance and Nutrition Research CentreNorthumbria UniversityMedicinal Plant Research GroupUniversities of NewcastleNorthumbria and DurhamSearch for other works by this author on:Emma L. Wightman;Emma L. WightmanBrain, Performance and Nutrition Research CentreNorthumbria UniversityMedicinal Plant Research GroupUniversities of NewcastleNorthumbria and DurhamSearch for other works by this author on:Edward J. OkelloEdward J. OkelloMedicinal Plant Research GroupUniversities of NewcastleNorthumbria and DurhamInstitute of NeurosciencesNewcastle UniversityNewcastle upon TyneUKSearch for other works by this author on:
Spotlight
Advertisement
Advertisement